Sanofi Pasteur Acquires Acne Vaccine and Treatment License - Drug Discovery & Development

Thank you for using! This service has been made possible by all our customers. In order to provide a sustainable, best of the breed RSS to Email experience, we've chosen to keep this as a paid subscription service. If you are satisfied with your free trial, please sign-up today. Subscriptions without a plan would soon be removed. Thank you!

Sanofi Pasteur, the vaccines division of Sanofi, announced a research and development collaboration with the University of California, San Diego on an immunological approach to acne prevention and treatment targeting the specific neutralization of Propionibacterium acnes factors in inflammation.

Acne vulgaris is associated with the Gram-positive anaerobic bacterium P. acnes that is a normal member of the human skin microflora. Current treatment of mild forms of acne involves killing P. acnes with bactericidal agents such as benzoyl peroxide and oral or topical antibiotics, all of which indiscriminately kill many bacterial species and disrupt the normal balance of the skin microflora.

Long-term use of antibiotics also leads to resistant strains of P. acnes. "This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," says Elias Zerhouni, MD, president, global research & development, Sanofi. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

The financial terms of the agreement were not disclosed. The agreement includes a two-year research collaboration with Chun-Ming Huang, MD and his associates at UC San Diego School of Medicine for further research and development.

Release Date: Sept. 21, 2011
Source: Sanofi Pasteur 

22 Sep, 2011

Manage subscription | Powered by

What's on Your Mind...

Powered by Blogger.